Matches in SemOpenAlex for { <https://semopenalex.org/work/W2933483331> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2933483331 abstract "Aim : To analyze the effectiveness of intravitreal injection of an anti-VEGF agent (ranibizumab) and an dexametazon implant for the intravitreal injection, in real clinical life. Patients and Methods . 137 patients with MO due to retinal venous occlusion were included in the study. Patients were retrospectively divided into groups: patients who received monotherapy with ranibizumab 94 people; and monotherapy with dexamethasone implant — 15 patients; patients who initially were injected with a dexamethasone implant, but due the study transferred to ranibizumab 15 patients; patients who initially received ranibizumab, but then transferred to the dexamethasone implant -13. For the treatment of macular edema were used an anti-VEGF agent — ranibizumab (Lucentis) 0.05 ml (0.5 mg) manufactured by Novartis (Switzerland) or glucocorticosteroid — dexamethasone implant for intravitreal injection of 0.7 mg (Ozurdex) manufactured by Allergan Pharmaceutical Ireland (Ireland). The injections were administered on a pro re nata basis (the presence of macular edema). Standard ophthalmological examination and fluorescent angiography (PAG), optical coherent tomography (OCT), optical coherence tomography angiography (OCT-A) were used. Visual acuity changes (BCVA), central retinal thickness (CRT) and intraocular pressure (IOP) were analyzed depending on the study group (group 1–4), the duration of treatment and the number of injections. Results : In group 1, from 1 to 8 IVVs were performed in 24 months, an average of 3.77. In group 2, from 1 to 4 intravitreal injections were performed in 24 months, an average of 1.37. In group 3, from 1 to 2 of intravitreal injections Ozurdex and from 1 to 4 intravitreal injections of ranibizumab for 24 months. In group 4, from 1 to 4 intravitreal injections of anti-VEGF drug and from 1 to 4 intravitreal dexamethasone implant were performed in 24 months of follow-up. Monotherapy with the Ozurdex drug (12 months) had the most stable effect, with a relapse of the process, repeated injections were required, conducted only in 3 out of 15 patients. Conclusion : In real clinical practice, the dexamethasone implant showed a good safety profile and high efficacy in the resorption of macular edema in patients with retinal vein occlusion, which corresponds to the clinical trials that was made earlier." @default.
- W2933483331 created "2019-04-11" @default.
- W2933483331 creator A5008749093 @default.
- W2933483331 creator A5024257423 @default.
- W2933483331 creator A5025606259 @default.
- W2933483331 creator A5039948866 @default.
- W2933483331 creator A5086212093 @default.
- W2933483331 date "2019-03-30" @default.
- W2933483331 modified "2023-10-06" @default.
- W2933483331 title "The Role of Steroids in the Management of Macular Edema from Retinal Vein Occlusion" @default.
- W2933483331 cites W2022621467 @default.
- W2933483331 cites W2031246040 @default.
- W2933483331 cites W2050555000 @default.
- W2933483331 cites W2075780935 @default.
- W2933483331 cites W2128701654 @default.
- W2933483331 cites W2419195469 @default.
- W2933483331 cites W2560332229 @default.
- W2933483331 cites W2803037198 @default.
- W2933483331 cites W4237391818 @default.
- W2933483331 doi "https://doi.org/10.18008/1816-5095-2019-1-95-101" @default.
- W2933483331 hasPublicationYear "2019" @default.
- W2933483331 type Work @default.
- W2933483331 sameAs 2933483331 @default.
- W2933483331 citedByCount "2" @default.
- W2933483331 countsByYear W29334833312020 @default.
- W2933483331 countsByYear W29334833312022 @default.
- W2933483331 crossrefType "journal-article" @default.
- W2933483331 hasAuthorship W2933483331A5008749093 @default.
- W2933483331 hasAuthorship W2933483331A5024257423 @default.
- W2933483331 hasAuthorship W2933483331A5025606259 @default.
- W2933483331 hasAuthorship W2933483331A5039948866 @default.
- W2933483331 hasAuthorship W2933483331A5086212093 @default.
- W2933483331 hasBestOaLocation W29334833311 @default.
- W2933483331 hasConcept C118487528 @default.
- W2933483331 hasConcept C126322002 @default.
- W2933483331 hasConcept C141071460 @default.
- W2933483331 hasConcept C2776268601 @default.
- W2933483331 hasConcept C2776694085 @default.
- W2933483331 hasConcept C2777802072 @default.
- W2933483331 hasConcept C2778257484 @default.
- W2933483331 hasConcept C2778844676 @default.
- W2933483331 hasConcept C2780347916 @default.
- W2933483331 hasConcept C2780401358 @default.
- W2933483331 hasConcept C2780699112 @default.
- W2933483331 hasConcept C2781092963 @default.
- W2933483331 hasConcept C2781100027 @default.
- W2933483331 hasConcept C2781411149 @default.
- W2933483331 hasConcept C2908732032 @default.
- W2933483331 hasConcept C71924100 @default.
- W2933483331 hasConceptScore W2933483331C118487528 @default.
- W2933483331 hasConceptScore W2933483331C126322002 @default.
- W2933483331 hasConceptScore W2933483331C141071460 @default.
- W2933483331 hasConceptScore W2933483331C2776268601 @default.
- W2933483331 hasConceptScore W2933483331C2776694085 @default.
- W2933483331 hasConceptScore W2933483331C2777802072 @default.
- W2933483331 hasConceptScore W2933483331C2778257484 @default.
- W2933483331 hasConceptScore W2933483331C2778844676 @default.
- W2933483331 hasConceptScore W2933483331C2780347916 @default.
- W2933483331 hasConceptScore W2933483331C2780401358 @default.
- W2933483331 hasConceptScore W2933483331C2780699112 @default.
- W2933483331 hasConceptScore W2933483331C2781092963 @default.
- W2933483331 hasConceptScore W2933483331C2781100027 @default.
- W2933483331 hasConceptScore W2933483331C2781411149 @default.
- W2933483331 hasConceptScore W2933483331C2908732032 @default.
- W2933483331 hasConceptScore W2933483331C71924100 @default.
- W2933483331 hasLocation W29334833311 @default.
- W2933483331 hasOpenAccess W2933483331 @default.
- W2933483331 hasPrimaryLocation W29334833311 @default.
- W2933483331 hasRelatedWork W18533627 @default.
- W2933483331 hasRelatedWork W20078794 @default.
- W2933483331 hasRelatedWork W20792805 @default.
- W2933483331 hasRelatedWork W3350394 @default.
- W2933483331 hasRelatedWork W3599615 @default.
- W2933483331 hasRelatedWork W3655396 @default.
- W2933483331 hasRelatedWork W3930305 @default.
- W2933483331 hasRelatedWork W4875113 @default.
- W2933483331 hasRelatedWork W543922 @default.
- W2933483331 hasRelatedWork W8098734 @default.
- W2933483331 isParatext "false" @default.
- W2933483331 isRetracted "false" @default.
- W2933483331 magId "2933483331" @default.
- W2933483331 workType "article" @default.